Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aclipse One Inc. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution landscape for the company is consolidated, involving only 1 distinct examiner and 1 distinct art unit at this time. This high level of concentration suggests that the company's current intellectual property efforts are focused on a specific niche within the broader biotechnology sector.
The busiest examiner, RAO, PADMAJA S, is responsible for 1 pending office action. This indicates that the company's current progress in the biotechnology sector is tied to the examination results from this specific individual. For the practitioner, this means that the 1 pending office action requires a deep understanding of this examiner's specific tendencies and the art unit's typical rejection patterns.
Because the company is dealing with only 1 distinct art unit, the prosecution strategy can remain uniform. The 1 pending office action represents the entirety of the current active challenges for Aclipse One Inc., making its successful resolution the primary objective for the company's Biotechnology & Pharmaceuticals portfolio. The 1 distinct examiner assigned to the case will be the primary arbiter of the company's patentability in this field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633143 | Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | RAO, PADMAJA S | 8d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17633143 | Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | RAO, PADMAJA S | 1627 | §103Other | Non-Final OA | 8d | Pending | Feb 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial